Successful Treatment of Immune Checkpoint Inhibitor–Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature
Jiazhen Chen, Duanni Xu, Zezhi He, Shaoyin Ma, Jiahui Liu, Xiangnong Dai, Yuwu Luo, Xingdong Ye · 2024
Read Successful Treatment of Immune Checkpoint Inhibitor–Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature by Jiazhen Chen, Duanni Xu, Zezhi He, Shaoyin Ma, Jiahui Liu, Xiangnong Dai, Yuwu Luo, Xingdong Ye (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11654213.txt.
Description
Jiazhen Chen and co-authors report a forty-eight-year-old woman with lung cancer who developed bullous pemphigoid, a blistering skin disease, after treatment with an immune checkpoint drug. Such drugs free the immune system against cancer but can turn it against the skin. Steroids, then stronger immune suppressants, failed to stop new blisters.
Her blood showed high IgE levels, so the team tried omalizumab, an antibody that targets IgE. Within one week the blistering stopped and symptoms eased. Four weeks of treatment brought stable improvement, and four months of follow-up showed no return. Reviewing the few published cases, the authors propose choosing biologic drugs for this condition by the patient's immune profile, including IgE, eosinophils, and cytokine levels.
Catalog record
| CREATOR | Jiazhen Chen, Duanni Xu, Zezhi He, Shaoyin Ma, Jiahui Liu, Xiangnong Dai, Yuwu Luo, Xingdong Ye |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |